ICON8: A GCIG phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: Results of primary progression- free survival (PFS) analysis
A. Clamp(The Christie NHS Foundation Trust), Jonathan A. Ledermann(London Cancer), Sally Stenning(Medical Research Council), David Gallardo(Instituto Nacional de Cancerología), Timothy Perren(University of Leeds), J. Weon-Kim(Seoul National University Hospital), James D. Brenton(Cambridge University Hospitals NHS Foundation Trust), Andrew Dean, Richard Kaplan(University College London), Sudha Sundar(Sandwell & West Birmingham Hospitals NHS Trust), Sarah P. Blagden(Churchill Hospital), Elizabeth C James(Royal Devon & Exeter NHS Foundation Trust), Ann Marie Swart(University of East Anglia), Raj Naik(Queen Elizabeth Hospital), Iain A. McNeish(Imperial College London), Dearbhaile M. O’Donnell, C. Coyle(MRC Clinical Trials Unit at UCL), Jane Hook(University of Leeds), Adrian Cook(University College London)
Cited by 51
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k